Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 3/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | TGM2 | P21980 | 1/20 | 0.63 |
| ▸ | KEAP1 | Q14145 | 3/20 | 0.60 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.51 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24990083 | 0.99 | TGM2 (0.65) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL19957878 | 0.99 | TGM2 (0.65) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL22166825 | 0.95 | HTT (0.68) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL5063193 | 0.89 | LMNA (0.77) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL18254066 | 0.89 | HTT (0.81) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL9874334 | 0.88 | HTT (0.79) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL15346534 | 0.88 | HTT (0.79) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL9340146 | 0.88 | HTT (0.79) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL14288938 | 0.87 | LMNA (0.69) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL18967940 | 0.87 | HTT (0.68) | HTTLMNASMN1; SMN2TGM2KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024073622-A2 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING EPHRIN TYPE-A RECEPTOR 2 AND USES THEREOF | RAYZEBIO, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| WO-2023014979-A9 | CONJUGATES COMPRISING COVALENT BINDERS FOR TARGETING INTRACELLULAR KRAS G12C PROTEINS | RAYZEBIO, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023014979-A1 | CONJUGATES COMPRISING COVALENT BINDERS FOR TARGETING INTRACELLULAR KRAS G12C PROTEINS | RAYZEBIO, INC. (US) | 2023-02-09 | — | — | WO | disclosed |
| EP-3293175-B1 | METHODS FOR PURIFICATION OF SERINE PROTEASES | ALEXION PHARMA INC (US) | 2021-12-01 | — | — | EP | disclosed |
| US-10590084-B2 | Cyclic keto-amide compounds as calpain modulators and methods of production and use thereof | BLADE THERAPEUTICS, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| US-20190194139-A1 | CYCLIC KETO-AMIDE COMPOUNDS AS CALPAIN MODULATORS AND METHODS OF PRODUCTION AND USE THEREOF | BLADE THERAPEUTICS, INC. (US) | 2019-06-27 | — | — | US | disclosed |
| EP-3293175-A1 | METHODS FOR PURIFICATION OF SERINE PROTEASES | Portola Pharmaceuticals, Inc. (US) | 2018-03-14 | — | — | EP | disclosed |
| EP-1474425-A1 | DEAZAPURINES AND USES THEREOF | Eisai Co. Ltd. (JP) | 2004-11-10 | — | — | EP | disclosed |
| WO-2004063336-A2 | USES OF DEAZAPURINES FOR THE TREATMENT OF REPERFUSION INJURIES, OSTEOPOROSIS AND/OR BONE METASTASIS | EISAI CO. LTD. (JP) | 2004-07-29 | — | — | WO | disclosed |
| WO-2003057696-A1 | DEAZAPURINES AND USES THEREOF | EISAI CO. LTD. (JP) | 2003-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194139-A1 | CYCLIC KETO-AMIDE COMPOUNDS AS CALPAIN MODULATORS AND METHODS OF PRODUCTION AND USE THEREOF | CAPN1, CAPN9, CAPN2 | HTT 4019/4885LMNA 236/4885SMN1; SMN2 2286/4885 |
| US-10590084-B2 | Cyclic keto-amide compounds as calpain modulators and methods of production and use thereof | CAPN1, CAPN9, CAPN2 | HTT 4019/4885LMNA 236/4885SMN1; SMN2 2286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.